Results of UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome The trial was run by the University of Nottingham, conducted between 18th March 2022 and 5th of March 2023, sponsored by Nottingham University Hospitals NHS Trust. The aim was to evaluate the effectiveness of the Neupulse device in…
Primary Progressive MS confirmed to be distinct from other MS subtypes
Long suspected by the research community, new study from Tisch MS Research Center of New York, published in Brain, finally establishes that PPMS is pathophysiologically separate from other forms of MS Findings have groundbreaking implications for targeted treatment of PPMS, a disease characterised by worsening neurological function and progressive disability in patients The Tisch MS…
‘Microbot’ development could help treat seizures
University of Glasgow researchers are part of a new project which is setting out to develop tiny injectable robots capable of predicting and mitigating epileptic seizures. The project, called CROSSBRAIN, is led by Tor Vergata University of Rome in Italy and is funded by the European Innovation Council. Over the course of the next four…
NICE publishes reimbursement recommendation for Translarna™
On 22nd February 2023, PTC Therapeutics, Ltd. announced the National Institute for Health and Care Excellence (NICE) has published its Final Guidance recommending Translarna™ (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales. Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged 2 years and older who can…
FINTEPLA®▼ (fenfluramine) oral solution approved in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
UCB’s FINTEPLA®▼ (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.1 The approval by the European Commission (EC) was based on safety and efficacy data from a…
NICE approves eptinezumab (Vyepti) to treat episodic and chronic migraine
On 25th January 2023, the National Institute for Health and Care Excellence (NICE) announced that eptinezumab (Vyepti) has been approved for use within the NHS in England for the treatment of episodic migraine. Eptinezumab is given by infusion once every 12 weeks. It is one of a number of calcitonin gene-related peptide (CGRP) antibody drugs, which are…
NICE Recommends Reimbursement for Translarna™
Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy PTC Therapeutics, Inc. today (19/1/23) announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation Document recommending Translarna™ (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales. Translarna is the…
Rozanolixizumab BLA for the treatment of generalised myasthenia gravis filed with US FDA and designated for priority review
UCB, a global biopharmaceutical company, announced on 6th January 2023 that the US Food and Drug Administration (FDA) has accepted the company’s filing to review a Biologic License Application (BLA) for its investigational treatment rozanolixizumab, and that the Agency has granted Priority Review.1 Rozanolixizumab is a subcutaneous (SC) monoclonal antibody targeting the neonatal Fc receptor…
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
FINTEPLA®▼ (fenfluramine) oral solution recommended for approval in the EU UCB, a global biopharmaceutical company, announced on 19th December 2022 that FINTEPLA®▼ (fenfluramine) oral solution has been recommended for marketing authorisation in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for…
